New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 2, 2013
12:39 EDTSGYPSynergy Pharmaceuticals price target raised to $13 from $7 at Cantor
Cantor increased its target on Synergy after the company reported results from a Phase III trial of its chronic constipation treatment, plecanatide, that the firm views as positive. The firm increased its E.U. and Japanese sales estimates for the drug, and it sees the company as a takeover target. Cantor believes that Synergy has multiple upcoming positive catalysts and it maintains a Buy rating.
News For SGYP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
06:06 EDTSGYPSynergy Pharm' presents positive data from phase 2b study of plecanatide
Synergy Pharmaceuticals announced the presentation of results from a phase 2b dose-ranging study assessing plecanatide’s safety and efficacy in 424 adult patients with irritable bowel syndrome with constipation. Data presented at ACG demonstrate that plecanatide, once-daily oral tablet, significantly improved complete spontaneous bowel movement frequency, bowel habits, treatment satisfaction and significantly reduced abdominal pain in patients with IBS-C throughout the 12 week treatment period. Notably, patients taking 3.0 and 9.0 mg plecanatide showed statistically significant improvement in the Overall Responder rate, a secondary analysis in this study and the endpoint required for FDA approval in IBS-C.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use